Moderna stock surges 6% as its vaccine produces antibodies against Delta variant

5:06 PM 29 June 2021

Moderna (MRNA.US) stock rose almost 6% after the drugmaker announced that its Covid-19 vaccine produced protective antibodies against the contagious delta variant. The mRNA vaccine produced neutralizing antibodies against all variants tested, including the delta, beta and eta, the company said in a statement. Additionally, news that India approved Moderna's vaccine for restricted emergency use also lifted sentiment towards the stock.

Moderna (MRNA.US) stock price rose sharply during today's session and hit a new all-time high at $238.22 which coincides with 127.2 external Fibonacci retracement. If the current sentiment prevails then the next target for bulls is located around $247.63 and is marked by 161.8 external Fibonacci retracement. Source: xStation5

Share:
Back

Join over 1 600 000 XTB Group Clients from around the world

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits